Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders

Complete Title: Allogeneic hematopoietic cell transplantation for patients with non-malignant disorders using Treosulfan, Fludarabine, and Thiotepa

Trial Phase: II

Investigator: Lauri Burroughs

This phase II trial studies how well donor stem cell transplant, treosulfan, fludarabine, and thiotepa work in treating patients with non-cancerous disorders. Giving chemotherapy before a donor transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. It may also stop the patient`s immune system from rejecting the donor`s stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient`s bone marrow make stem cells, red blood cells, white blood cells, and platelets. The donated stem cells may also replace the patient`s immune cells and help destroy any remaining cancer cells.

Keywords:

Neoplasms

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Join a Clinical Trial

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.

Contact Us

If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.